Articles
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL plus today's featured jobs. To see the entire bulletin click here Breaking News (from DailyUpdates-Cancer Immunotherapy): Micromet develops new lymphoma thera…
Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets. Xyotax (pa…
Todays Headlines from across the DailyUpdates network. In today's edition (see it in full) we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus Breaking News (from DailyUpdates-Oncology): Locus Pharmaceuticals about to enter the clinic with novel cell cycle r…
Todays Headlines from across the DailyUpdates network (access DailyUpdates 15th June, 2006 here) Breaking News (from DailyUpdates-Oncology): CuraGen and TopoTarget to test the promising combination of HDAC inhibition and retinoic acid receptor activation in patients with solid tumors The histone deacetylase inhibitor class of therapeutics represents a highly exciting approach to cancer. Merck's ZOLINZA (SAHA; vorinostat) and Gloucester Pharmaceuticals' Depsipeptide (FK228) lead this class however . Both candidates are evaluated in our fea…
Administering treatment in community oncology units achieves results that match those of specialist centres, according to the MABEL study; and phase III trials in the US and Europe are now focusing on investigating Erbitux as a first-line therapy option for mCRC. Fortnightly regimen could make life eas…
Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug. The trial will measure the effectiveness of VX-950 in combin…
Todays Headlines from across the DailyUpdates network (June 12th, 2006 - access this edition) Breaking News (from DailyUpdates-Metabolic Disorders): Metabolex announce phase II/III trial of novel insulin sensitizer Diabetes affects approximately 170 million people worldwide a figure that is increasing with the WHO predicting 300 million diabetics by 2025 (see The World Diabetes Market, 2005-2011). The alone has 20.8 million people suffering with dia…
Welcome! Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects…
Todays Headlines from across the DailyUpdates network (9th June 2006) Breaking News (from DailyUpdates-Infectious Diseases): Merck wins the race for HPV vaccine approval in the US HPV is the most commonly diagnosed viral sexually transmitted disease in the and , with conservative annual incidence estimates of 5.5 million in the alone. Over 100 types of HPV, causing a variety of diseases, have been identified. It is believed that 50-75% of HPV infections involve high-risk HPV types, leading to approximately 500,000 new cases of cervical cancer and 232,000 deaths worldwide each year. Treatment options are limited, with no k…
DailyUpdates 31st May: Today's edition of DailyUpdates focuses on a controversial area of neurotransmission: opioids, cannabinoids and their overlap. Our featured press release is from Allon Therapeutics and announces further progress on their novel approach to neurodegenerative disorders. Read on for an overview or visit today's edition of DailyUpdates hereCannabinoids and opioids - their intereaction in the modulation of pain: Canna…
ASCO 2006 Stimuvax, first therapeutic vaccine for lung cancer, to start Phase III trial Stimuvax (L-BLP 25), a therapeutic vaccine in development for non-small cell lung cancer (NSCLC), should enter Phase III testing this autumn. The START (Stimulating Targeted Antigenic Response to NSCLC Trial ) p…
DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from bloo…
Osteoarthritis (OA) is a degeneration of the joints characterized by progressive destruction of articular cartilage and articular structures. It is a complex process that involves multiple changes in joint structure and, according to Datamonitor estimates, affects 89 million adults in the seven major pharmaceutical markets. Due to the current widespread nature of the condition, the World Health…
DailyUpdates 6th June: As ASCO continues in full swing, we again focus on oncology. Today's edition of DailyUpdates includes 10 new papers on oncology research plus a further 20 or so press releases from companies presenting at ASCO. This is of course in addition to the rest of our content from acro…
DailyUpdates 5th June, 2006: With ASCO (The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX v…
Go to any of Euroscicon meeting in June and July and receive 50% off the delegate registration Just use the discount code – PharmiWeb – during online registration to receive 50% off the registration fee for the following events Assigning Gene Function - novel technologies & high throughput This will be an exciting meeting which will cover novel genomic technologies and the use of bioinformatics in high throughput data analysis. It will feature academic and industry seminars. Meetings Chair: Dr. Irina Udalova, Kennedy Institute of Rheumatology, Date: 16th June Venue: , Web: www.regonline.co.uk/genefunction Developing Technologies in Cytokine Detection Detection of cytokines is…
In December 2005, the New England Journal of Medicine published the first results of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) (1). The 18-month, double-blind study, funded by the US National Institute of Mental Health (NIMH), compared an older and much cheaper ty…
DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant desvenlafaxine. Read on for more about these highlight on visit today's edition of DailyUpdates for more on these advances or any of the other 50+ items featured todayDefining the problem of sepsis: Sepsis, a complex and rapidly progressing d…
Carcinoid cancer is a rare neuroendocrine tumor that is on the increase. In the , 6,000 to 7,000 new cases are confirmed each year, with 2,500 tumors at the malignant stage. The majority (85%) of carcinoid cancers develop within the gastrointestinal tract between the stomach and the rectum. Several tumors may develop in the small intestine, which often increases the risk of developing other tumors wi…
DailyUpdates 30th May: As the drug discovery sector returns after various public holidays around the world, we too return with another edition of DailyUpdates. Amongst the 60 or so features today, we highlight work at Kane Biotech conducted in an attempt to reduce the major problem of catheter infec…